Physiology of the vasopressin receptors

Best Practice and Research: Clinical Anaesthesiology

Volumn 22, Issue 2, 2008, Pages 253-263

  Maybauer, Marc O ^a   Maybauer, Dirk M ^a   Enkhbaatar, Perenlei ^a   Traber, Daniel L ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

amino acid sequences; arginine vasopressin (AVP); hypovolemia; oxytocin (ot); sepsis; V1 receptor agonist; vasopressin; vasopressin (VP)

Indexed keywords

ADRENALIN; ARGIPRESSIN; ARGIPRESSIN DERIVATIVE; CATECHOLAMINE; CORTICOTROPIN; HORMONE RECEPTOR; OXYTOCIN; OXYTOCIN RECEPTOR; PURINERGIC P2 RECEPTOR; SEX HORMONE; TERLIPRESSIN; VASOACTIVE AGENT; VASOPRESSIN; VASOPRESSIN RECEPTOR; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1 RECEPTOR AGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1A RECEPTOR AGONIST; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V3 RECEPTOR;

ADENOHYPOPHYSIS; ANTIDIURESIS; BINDING AFFINITY; BLEEDING; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARBOXY TERMINAL SEQUENCE; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CORTICOTROPIN RELEASE; DRUG EFFICACY; DRUG MECHANISM; FLUID RESUSCITATION; HEPATORENAL SYNDROME; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN GENOME; HYPOPHYSIS ADRENAL SYSTEM; HYPOTENSION; HYPOVOLEMIA; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MORTALITY; NEPHROGENIC DIABETES INSIPIDUS; NEUROGENIC DIABETES INSIPIDUS; NEUROTRANSMISSION; NONHUMAN; OSMOLARITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; RESUSCITATION; REVIEW; RISK REDUCTION; SECOND MESSENGER; SEPTIC SHOCK; SHOCK; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC VASCULAR RESISTANCE; TACHYPHYLAXIS; TISSUE DISTRIBUTION; VASOCONSTRICTION;

ANIMALS; HUMANS; MOLECULAR CONFORMATION; RECEPTORS, OXYTOCIN; RECEPTORS, PURINERGIC; RECEPTORS, VASOPRESSIN;

EID: 44949232034     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2008.03.003     Document Type: Review

References (51)

1. Oliver G., and Schafer E.A. On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication. The Journal of Physiology 18 3 (1895) 277-279
2. Du Vigneaud V., Ressler C., and Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. The Journal of Biological Chemistry 205 2 (1953) 949-957
3. Caldwell H.K., and Young W.S. Oxytocin and vasopressin: genetics and behavioral implications. In: Lim R. (Ed). Handbook of neurochemistry and molecular neurobiology: neuroactive proteins and peptides. 3rd ed. (2006), Springer, New York 573-607
4. Barberis C., Mouillac B., and Durroux T. Structural bases of vasopressin/oxytocin receptor function. The Journal of Endocrinology 156 2 (1998) 223-229
5. Riddell D.C., Mallonee R., Phillips J.A., et al. Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somatic Cell and Molecular Genetics 11 2 (1985) 189-195
6. Holmes C.L., Landry D.W., and Granton J.T. Science review: vasopressin and the cardiovascular system part 2-clinical physiology. Critical Care (London, England) 8 1 (2004) 15-23
7. Ertmer C., Bone H.G., Morelli A., et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock (Augusta, Ga.) 27 3 (2007) 281-288
8. Bassi G., Radermacher P., and Calzia E. Catecholamines and vasopressin during critical illness. Endocrinology and Metabolism Clinics of North America 35 4 (2006) 839-857 x
9. Holmes C.L., Landry D.W., and Granton J.T. Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Critical Care (London, England) 7 6 (2003) 427-434
10. Thibonnier M., Graves M.K., Wagner M.S., et al. Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene. Genomics 31 3 (1996) 327-334
11. Lange M., Ertmer C., and Westphal M. Vasopressin vs. terlipressinin the treatmentof cardiovascular failure in sepsis. Intensive Care Medicine (2007)
12. Johnston C.I. Vasopressin in circulatory control and hypertension. Journal of Hypertension 3 6 (1985) 557-569
13. Abboud F.M., Floras J.S., Aylward P.E., et al. Role of vasopressin in cardiovascular and blood pressure regulation. Blood Vessels 27 2-5 (1990) 106-115
14. Bishop V.S., and Hay M. Involvement of the area postrema in the regulation of sympathetic outflow to the cardiovascular system. Frontiers in Neuroendocrinology 14 2 (1993) 57-75
15. Aki Y., Tamaki T., Kiyomoto H., et al. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation. Journal of Cardiovascular Pharmacology 23 2 (1994) 331-336
16. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovascular Research 51 3 (2001) 372-390
17. Tahara A., Saito M., Tsukada J., et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. European Journal of Pharmacology 368 1 (1999) 89-94
18. Birnbaumer M., Seibold A., Gilbert S., et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 357 6376 (1992) 333-335
19. Seibold A., Brabet P., Rosenthal W., et al. Structure and chromosomal localization of the human antidiuretic hormone receptor gene. American Journal of Human Genetics 51 5 (1992) 1078-1083
20. Nielsen S., Frokiaer J., Marples D., et al. Aquaporins in the kidney: from molecules to medicine. Physiological Reviews 82 1 (2002) 205-244
21. Deen P.M., Verdijk M.A., Knoers N.V., et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 264 5155 (1994) 92-95
22. Sasaki S., Fushimi K., Saito H., et al. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. The Journal of Clinical Investigation 93 3 (1994) 1250-1256
23. Fujiwara T.M., and Bichet D.G. Molecular biology of hereditary diabetes insipidus. Journal of the American Society of Nephrology: JASN 16 10 (2005) 2836-2846
24. Saito M., Tahara A., Sugimoto T., et al. Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor. European Journal of Pharmacology 401 3 (2000) 289-296
25. Bichet D.G., Razi M., Lonergan M., et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. The New England Journal of Medicine 318 14 (1988) 881-887
26. Thibonnier M., Preston J.A., Dulin N., et al. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 138 10 (1997) 4109-4122
27. Rousseau-Merck M.F., Rene P., Derre J., et al. Chromosomal localization of the human V3 pituitary vasopressin receptor gene (AVPR3) to 1q32. Genomics 30 2 (1995) 405-406
28. Lee B., Yang C., Chen T.H., et al. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. The American Journal of Physiology 269 6 Pt 1 (1995) E1095-E1100
29. Kimura T., Makino Y., Saji F., et al. Molecular characterization of a cloned human oxytocin receptor. European Journal of Endocrinology 131 4 (1994) 385-390
30. Gimpl G., and Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological Reviews 81 2 (2001) 629-683
31. Young L.J., Wang Z., and Insel T.R. Neuroendocrine bases of monogamy. Trends in Neurosciences 21 2 (1998) 71-75
32. Insel T.R., Winslow J.T., Wang Z., et al. Oxytocin, vasopressin, and the neuroendocrine basis of pair bond formation. Advances in Experimental Medicine and Biology 449 (1998) 215-224
33. Sanborn B.M., Dodge K., Monga M., et al. Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium. Advances in Experimental Medicine and Biology 449 (1998) 277-286
34. Soloff M.S., and Sweet P. Oxytocin inhibition of (Ca2+ + Mg2+)-ATPase activity in rat myometrial plasma membranes. The Journal of Biological Chemistry 257 18 (1982) 10687-10693
35. Gutkowska J., Jankowski M., Lambert C., et al. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proceedings of the National Academy of Sciences of the United States of America 94 21 (1997) 11704-11709
36. Abbracchio M.P., Burnstock G., Boeynaems J.M., et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacolical Reviews 58 3 (2006) 281-341
37. Boarder M.R., Weisman G.A., Turner J.T., et al. G protein-coupled P2 purinoceptors: from molecular biology to functional responses. Trends in Pharmacological Sciences 16 4 (1995) 133-139
38. Mei Q., and Liang B.T. P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts. American Journal of Physiology. Heart and Circulatory Physiology 281 1 (2001) H334-H341
39. Zenteno-Savin T., Sada-Ovalle I., Ceballos G., et al. Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. European Journal Pharmacology 410 1 (2000) 15-23
40. Escorsell A., Ruiz del Arbol L., Planas R., et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (Baltimore, Md.) 32 3 (2000) 471-476
41. Landry D.W., Levin H.R., Gallant E.M., et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 5 (1997) 1122-1125
42. Wenzel V., Krismer A.C., Arntz H.R., et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. The New England Journal of Medicine 350 2 (2004) 105-113
43. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. [review] [162 refs]. Shock (Augusta, Ga.) 6 (1996) 79-88
44. Asfar P., Hauser B., Ivanyi Z., et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Critical Care Medicine 33 2 (2005) 373-380
45. Landry D.W., and Oliver J.A. The pathogenesis of vasodilatory shock. The New England Journal of Medicine 345 8 (2001) 588-595
46. Asfar P., Hauser B., Radermacher P., et al. Catecholamines and vasopressin during critical illness. Critical Care Medicine 22 1 (2006) 131-149 vii-viii
47. Martikainen T.J., Tenhunen J.J., Uusaro A., et al. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesthesia and Analgesia 97 6 (2003) 1756-1763
48. Asfar P., Pierrot M., Veal N., et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Critical Care Medicine 31 1 (2003) 215-220
49. Sun Q., Dimopoulos G., Nguyen D.N., et al. Low-dose vasopressin in the treatment of septic shock in sheep. American Journal of Respiratory and Critical Care Medicine 168 4 (2003) 481-486
50. Kaufmann J.E., Iezzi M., and Vischer U.M. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. Journal of Thrombosis and Haemostasis: JTH 1 4 (2003) 821-828
51. Bernat A., Hoffmann P., Dumas A., et al. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. The Journal of Pharmacology and Experimental Therapeutics 282 2 (1997) 597-602